QNCX
Income statement / Annual
Last year (2025), Quince Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Quince Therapeutics Inc's net income was -$83.98 M.
See Quince Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$142.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$51.00 K
|
$45.00 K
|
| Gross Profit |
-$142.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$51.00 K
|
-$45.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$35.38 M
|
$18.59 M
|
$9.45 M
|
$25.18 M
|
$60.80 M
|
$61.31 M
|
$30.21 M
|
$10.09 M
|
$9.10 M
|
| General & Administrative Expenses |
$15.05 M
|
$17.58 M
|
$17.70 M
|
$26.01 M
|
$29.52 M
|
$17.59 M
|
$8.95 M
|
$2.03 M
|
$1.27 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$15.05 M
|
$17.58 M
|
$17.70 M
|
$26.01 M
|
$29.52 M
|
$17.59 M
|
$8.95 M
|
$2.03 M
|
$1.27 M
|
| Other Expenses |
-$142.00 K
|
$21.12 M
|
$7.48 M
|
$825.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$50.29 M
|
$57.29 M
|
$34.62 M
|
$52.02 M
|
$90.32 M
|
$78.89 M
|
$39.17 M
|
$12.12 M
|
$10.37 M
|
| Cost And Expenses |
$50.43 M
|
$57.29 M
|
$34.62 M
|
$52.02 M
|
$90.32 M
|
$78.89 M
|
$39.17 M
|
$12.12 M
|
$10.37 M
|
| Interest Income |
$1.24 M
|
$2.93 M
|
$3.48 M
|
$1.07 M
|
$620.00 K
|
$2.04 M
|
$2.19 M
|
$806.00 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$568.00 K
|
$0.00
|
$0.00
|
$0.00
|
$957.00 K
|
$1.64 M
|
| Depreciation & Amortization |
$142.00 K
|
$186.00 K
|
$322.00 K
|
$204.00 K
|
$344.00 K
|
$332.00 K
|
$188.00 K
|
$51.00 K
|
$45.00 K
|
| EBITDA |
-$50.29 M |
-$35.98 M |
-$26.82 M |
-$50.99 M |
-$89.97 M |
-$78.56 M |
-$38.98 M |
-$12.07 M |
-$10.33 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$30.34 M
|
$544.00 K
|
$3.04 M
|
$71.00 K
|
$373.00 K
|
$2.04 M
|
$2.19 M
|
-$357.00 K
|
-$1.87 M
|
| Income Before Tax |
-$80.77 M
|
-$56.74 M
|
-$31.58 M
|
-$51.94 M
|
-$89.95 M
|
-$76.85 M
|
-$36.98 M
|
-$12.48 M
|
-$12.24 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$3.21 M
|
$87.00 K
|
-$197.00 K
|
-$284.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$83.98 M
|
-$56.83 M
|
-$31.39 M
|
-$51.66 M
|
-$89.95 M
|
-$76.85 M
|
-$36.98 M
|
-$12.48 M
|
-$12.24 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-16.8 |
-13.1 |
-8.4 |
-15.4 |
-30.3 |
-26.3 |
-19.3 |
-5.8 |
-5.7 |
| EPS Diluted |
-16.8 |
-13.1 |
-8.4 |
-15.4 |
-30.3 |
-26.3 |
-19.3 |
-5.8 |
-5.7 |
| Weighted Average Shares Out |
$5.01 M
|
$4.33 M
|
$3.72 M
|
$3.35 M
|
$2.97 M
|
$2.92 M
|
$1.90 M
|
$2.16 M
|
$2.16 M
|
| Weighted Average Shares Out Diluted |
$5.01 M
|
$4.33 M
|
$3.72 M
|
$3.35 M
|
$2.97 M
|
$2.92 M
|
$1.90 M
|
$2.16 M
|
$2.16 M
|
| Link |
|
|
|
|
|
|
|
|
|
